智通财经APP获悉，据知情人士透露，由于担心在印度这一潜力巨大的市场上落后于竞争对手礼来(LLY.US)，丹麦制药巨头诺和诺德(NVO.US)的印度团队一直在推动该公司在印度更早推出其广受欢迎的减肥药Wegovy，以保持其在全球范围减肥药市场中的领导 ...

诺和诺德 (NVO.US)美股盘前涨2%。消息上，由于担心在印度这一潜力巨大的市场上落后于竞争对手 礼来 ，丹麦制药巨头诺和诺德的印度团队一直在推动该公司在印度更早推出其广受欢迎的减肥药Wegovy。 (格隆汇) ...

财联社12月3日讯（编辑 夏军雄） 据媒体援引消息人士报道，丹麦制药巨头诺和诺德在印度的团队一直在敦促该公司高层尽快在当地推出其明星减肥药物Wegovy，以避免在印度这个潜在的巨大市场落后于竞争对手礼来公司。

36氪获悉，日出东方公告，公司高级管理人员焦青太收到江苏证监局警示函。焦青太的配偶孙克美通过其账户买卖公司股票，2024年6月6日至2024年6月19日买入18.87万股，成交金额70.55万元，2024年11月7日卖出4.94万股，成交金额32.2 ...

Doctors say early obesity intervention can help prevent later health problems. But prescribing GLP-1s, such as Ozempic and ...

Novo Nordisk's team in India has been pushing the Danish drugmaker's global leadership for an earlier launch of its popular ...

Biden’s Center for Medicare and Medicaid Services extends coverage by making nonsense of the law.

Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

As with any prescription medication, there are side effects of Wegovy to keep in mind. The most common side effects are ...

Novo Nordisk's team in India has been pushing the Danish drugmaker's global leadership for an earlier launch of its popular ...

Officials at the Danish drugmaker have said Wegovy might be introduced in India in 2026 once regulatory approvals are in hand ...

Millions of Americans would be eligible to have popular drugs used for weight loss like Wegovy or Ozempic covered by Medicare ...